APO Research
Talk to an analyst

APO RESEARCH · REPORT

NASH Drug Pipeline

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global NASH Drug Pipeline Market Outlook and Growth Opportunities 2026

2 January 2026218 pages

Choose your research edition.

Industry ResearchNASH Drug Pipeline Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal NASH Drug Pipeline Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal NASH Drug Pipeline Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal NASH Drug Pipeline Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal NASH Drug Pipeline Market Analysis and Forecast 2026-2032218 pages · $4,950 USD

Market perspective

The global NASH Drug Pipeline market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for NASH Drug Pipeline is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for NASH Drug Pipeline is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for NASH Drug Pipeline is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the NASH Drug Pipeline market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the NASH Drug Pipeline market include 89bio Inc, ABIONYX Pharma SA, Abivax SA, Abliva AB, Acquist Therapeutics, AdAlta Ltd, Afimmune Biopharma Ltd, Allergan and ChemomAb Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global NASH Drug Pipeline market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of NASH Drug Pipeline and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents NASH Drug Pipeline sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the NASH Drug Pipeline market size, projected growth trends, production technologies, key applications, and end-use industries.

NASH Drug Pipeline Segment by Company

89bio Inc

ABIONYX Pharma SA

Abivax SA

Abliva AB

Acquist Therapeutics

AdAlta Ltd

Afimmune Biopharma Ltd

Allergan

ChemomAb Ltd

Dicerna Pharmaceuticals Inc

DURECT Corp

Eli Lilly and Co

Enanta Pharmaceuticals Inc

EncuraGen Inc

Engitix Ltd

Galectin

Genfit

Gilead

Heprotech Inc

Hinova Pharmaceuticals Inc

HK inno.N Corp

HotSpot Therapeutics Inc

Immuron

Intercept

Madrigal

Zhejiang Doer Biologics Corp

NASH Drug Pipeline Segment by Type

By Molecule Types

By Route of Administration:

By Mechanism of Action

NASH Drug Pipeline Segment by Application

Clinical

Academic Research

NASH Drug Pipeline Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global NASH Drug Pipeline status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions NASH Drug Pipeline market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify NASH Drug Pipeline significant trends, drivers, influence factors in global and regions.

6. To analyze NASH Drug Pipeline competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NASH Drug Pipeline market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of NASH Drug Pipeline and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NASH Drug Pipeline.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the NASH Drug Pipeline market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global NASH Drug Pipeline industry.

Chapter 3: Detailed analysis of NASH Drug Pipeline manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of NASH Drug Pipeline in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of NASH Drug Pipeline in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. NASH Drug Pipeline Industry Trends Table 2. NASH Drug Pipeline Industry Drivers Table 3. NASH Drug Pipeline Industry Opportunities and Challenges Table 4. NASH Drug Pipeline Industry Restraints Table 5. Global NASH Drug Pipeline Revenue by Company (US$ Million) & (2021-2026) Table 6. Global NASH Drug Pipeline Revenue Share by Company (2021-2026) Table 7. Global NASH Drug Pipeline Sales Volume by Company (K Units) & (2021-2026) Table 8. Global NASH Drug Pipeline Sales Volume Share by Company (2021-2026) Table 9. Global NASH Drug Pipeline Average Price (US$/Unit) of Company (2021-2026) Table 10. Global NASH Drug Pipeline Company Ranking, (2024-2026) & (USD Million) Table 11. Global NASH Drug Pipeline Key Company Manufacturing Base & Headquarters Table 12. Global NASH Drug Pipeline Company, Product Type & Application Table 13. Global NASH Drug Pipeline Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global NASH Drug Pipeline by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Type One Table 18. Significant Companies of Type Two Table 19. Global NASH Drug Pipeline Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global NASH Drug Pipeline Sales Volume by Type (2021-2026) & (K Units) Table 21. Global NASH Drug Pipeline Sales Volume by Type (2027-2032) & (K Units) Table 22. Global NASH Drug Pipeline Sales Volume Share by Type (2021-2026) Table 23. Global NASH Drug Pipeline Sales Volume Share by Type (2027-2032) Table 24. Global NASH Drug Pipeline Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global NASH Drug Pipeline Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global NASH Drug Pipeline Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global NASH Drug Pipeline Sales Value Share by Type (2021-2026) Table 28. Global NASH Drug Pipeline Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Clinical Table 30. Significant Companies of Academic Research Table 31. Global NASH Drug Pipeline Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global NASH Drug Pipeline Sales Volume by Application (2021-2026) & (K Units) Table 33. Global NASH Drug Pipeline Sales Volume by Application (2027-2032) & (K Units) Table 34. Global NASH Drug Pipeline Sales Volume Share by Application (2021-2026) Table 35. Global NASH Drug Pipeline Sales Volume Share by Application (2027-2032) Table 36. Global NASH Drug Pipeline Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global NASH Drug Pipeline Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global NASH Drug Pipeline Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global NASH Drug Pipeline Sales Value Share by Application (2021-2026) Table 40. Global NASH Drug Pipeline Sales Value Share by Application (2027-2032) Table 41. Global NASH Drug Pipeline Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global NASH Drug Pipeline Sales by Region (2021-2026) & (K Units) Table 43. Global NASH Drug Pipeline Sales Market Share by Region (2021-2026) Table 44. Global NASH Drug Pipeline Sales by Region (2027-2032) & (K Units) Table 45. Global NASH Drug Pipeline Sales Market Share by Region (2027-2032) Table 46. Global NASH Drug Pipeline Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global NASH Drug Pipeline Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global NASH Drug Pipeline Sales Value Share by Region (2021-2026) Table 49. Global NASH Drug Pipeline Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global NASH Drug Pipeline Sales Value Share by Region (2027-2032) Table 51. Global NASH Drug Pipeline Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global NASH Drug Pipeline Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global NASH Drug Pipeline Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Global NASH Drug Pipeline Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global NASH Drug Pipeline Sales by Country (2021-2026) & (K Units) Table 56. Global NASH Drug Pipeline Sales Market Share by Country (2021-2026) Table 57. Global NASH Drug Pipeline Sales by Country (2027-2032) & (K Units) Table 58. Global NASH Drug Pipeline Sales Market Share by Country (2027-2032) Table 59. Global NASH Drug Pipeline Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global NASH Drug Pipeline Sales Value Market Share by Country (2021-2026) Table 61. Global NASH Drug Pipeline Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global NASH Drug Pipeline Sales Value Market Share by Country (2027-2032) Table 63. 89bio Inc Company Information Table 64. 89bio Inc Business Overview Table 65. 89bio Inc NASH Drug Pipeline Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. 89bio Inc NASH Drug Pipeline Product Portfolio Table 67. 89bio Inc Recent Development Table 68. ABIONYX Pharma SA Company Information Table 69. ABIONYX Pharma SA Business Overview Table 70. ABIONYX Pharma SA NASH Drug Pipeline Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. ABIONYX Pharma SA NASH Drug Pipeline Product Portfolio Table 72. ABIONYX Pharma SA Recent Development Table 73. Abivax SA Company Information Table 74. Abivax SA Business Overview Table 75. Abivax SA NASH Drug Pipeline Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Abivax SA NASH Drug Pipeline Product Portfolio Table 77. Abivax SA Recent Development Table 78. Abliva AB Company Information Table 79. Abliva AB Business Overview Table 80. Abliva AB NASH Drug Pipeline Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Abliva AB NASH Drug Pipeline Product Portfolio Table 82. Abliva AB Recent Development Table 83. Acquist Therapeutics Company Information Table 84. Acquist Therapeutics Business Overview Table 85. Acquist Therapeutics NASH Drug Pipeline Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Acquist Therapeutics NASH Drug Pipeline Product Portfolio Table 87. Acquist Therapeutics Recent Development Table 88. AdAlta Ltd Company Information Table 89. AdAlta Ltd Business Overview Table 90. AdAlta Ltd NASH Drug Pipeline Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. AdAlta Ltd NASH Drug Pipeline Product Portfolio Table 92. AdAlta Ltd Recent Development Table 93. Afimmune Biopharma Ltd Company Information Table 94. Afimmune Biopharma Ltd Business Overview Table 95. Afimmune Biopharma Ltd NASH Drug Pipeline Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Afimmune Biopharma Ltd NASH Drug Pipeline Product Portfolio Table 97. Afimmune Biopharma Ltd Recent Development Table 98. Allergan Company Information Table 99. Allergan Business Overview Table 100. Allergan NASH Drug Pipeline Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Allergan NASH Drug Pipeline Product Portfolio Table 102. Allergan Recent Development Table 103. ChemomAb Ltd Company Information Table 104. ChemomAb Ltd Business Overview Table 105. ChemomAb Ltd NASH Drug Pipeline Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. ChemomAb Ltd NASH Drug Pipeline Product Portfolio Table 107. ChemomAb Ltd Recent Development Table 108. Dicerna Pharmaceuticals Inc Company Information Table 109. Dicerna Pharmaceuticals Inc Business Overview Table 110. Dicerna Pharmaceuticals Inc NASH Drug Pipeline Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Dicerna Pharmaceuticals Inc NASH Drug Pipeline Product Portfolio Table 112. Dicerna Pharmaceuticals Inc Recent Development Table 113. DURECT Corp Company Information Table 114. DURECT Corp Business Overview Table 115. DURECT Corp NASH Drug Pipeline Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. DURECT Corp NASH Drug Pipeline Product Portfolio Table 117. DURECT Corp Recent Development Table 118. Eli Lilly and Co Company Information Table 119. Eli Lilly and Co Business Overview Table 120. Eli Lilly and Co NASH Drug Pipeline Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Eli Lilly and Co NASH Drug Pipeline Product Portfolio Table 122. Eli Lilly and Co Recent Development Table 123. Enanta Pharmaceuticals Inc Company Information Table 124. Enanta Pharmaceuticals Inc Business Overview Table 125. Enanta Pharmaceuticals Inc NASH Drug Pipeline Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Enanta Pharmaceuticals Inc NASH Drug Pipeline Product Portfolio Table 127. Enanta Pharmaceuticals Inc Recent Development Table 128. EncuraGen Inc Company Information Table 129. EncuraGen Inc Business Overview Table 130. EncuraGen Inc NASH Drug Pipeline Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. EncuraGen Inc NASH Drug Pipeline Product Portfolio Table 132. EncuraGen Inc Recent Development Table 133. Engitix Ltd Company Information Table 134. Engitix Ltd Business Overview Table 135. Engitix Ltd NASH Drug Pipeline Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Engitix Ltd NASH Drug Pipeline Product Portfolio Table 137. Engitix Ltd Recent Development Table 138. Galectin Company Information Table 139. Galectin Business Overview Table 140. Galectin NASH Drug Pipeline Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. Galectin NASH Drug Pipeline Product Portfolio Table 142. Galectin Recent Development Table 143. Genfit Company Information Table 144. Genfit Business Overview Table 145. Genfit NASH Drug Pipeline Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 146. Genfit NASH Drug Pipeline Product Portfolio Table 147. Genfit Recent Development Table 148. Gilead Company Information Table 149. Gilead Business Overview Table 150. Gilead NASH Drug Pipeline Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 151. Gilead NASH Drug Pipeline Product Portfolio Table 152. Gilead Recent Development Table 153. Heprotech Inc Company Information Table 154. Heprotech Inc Business Overview Table 155. Heprotech Inc NASH Drug Pipeline Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 156. Heprotech Inc NASH Drug Pipeline Product Portfolio Table 157. Heprotech Inc Recent Development Table 158. Hinova Pharmaceuticals Inc Company Information Table 159. Hinova Pharmaceuticals Inc Business Overview Table 160. Hinova Pharmaceuticals Inc NASH Drug Pipeline Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 161. Hinova Pharmaceuticals Inc NASH Drug Pipeline Product Portfolio Table 162. Hinova Pharmaceuticals Inc Recent Development Table 163. HK inno.N Corp Company Information Table 164. HK inno.N Corp Business Overview Table 165. HK inno.N Corp NASH Drug Pipeline Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 166. HK inno.N Corp NASH Drug Pipeline Product Portfolio Table 167. HK inno.N Corp Recent Development Table 168. HotSpot Therapeutics Inc Company Information Table 169. HotSpot Therapeutics Inc Business Overview Table 170. HotSpot Therapeutics Inc NASH Drug Pipeline Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 171. HotSpot Therapeutics Inc NASH Drug Pipeline Product Portfolio Table 172. HotSpot Therapeutics Inc Recent Development Table 173. Immuron Company Information Table 174. Immuron Business Overview Table 175. Immuron NASH Drug Pipeline Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 176. Immuron NASH Drug Pipeline Product Portfolio Table 177. Immuron Recent Development Table 178. Intercept Company Information Table 179. Intercept Business Overview Table 180. Intercept NASH Drug Pipeline Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 181. Intercept NASH Drug Pipeline Product Portfolio Table 182. Intercept Recent Development Table 183. Madrigal Company Information Table 184. Madrigal Business Overview Table 185. Madrigal NASH Drug Pipeline Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 186. Madrigal NASH Drug Pipeline Product Portfolio Table 187. Madrigal Recent Development Table 188. Zhejiang Doer Biologics Corp Company Information Table 189. Zhejiang Doer Biologics Corp Business Overview Table 190. Zhejiang Doer Biologics Corp NASH Drug Pipeline Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 191. Zhejiang Doer Biologics Corp NASH Drug Pipeline Product Portfolio Table 192. Zhejiang Doer Biologics Corp Recent Development Table 193. Key Raw Materials Table 194. Raw Materials Key Suppliers Table 195. NASH Drug Pipeline Distributors List Table 196. NASH Drug Pipeline Customers List Table 197. Research Programs/Design for This Report Table 198. Authors List of This Report Table 199. Secondary Sources Table 200. Primary Sources List of Figures Figure 1. NASH Drug Pipeline Product Image Figure 2. Global NASH Drug Pipeline Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global NASH Drug Pipeline Sales Value (2021-2032) & (US$ Million) Figure 4. Global NASH Drug Pipeline Sales (2021-2032) & (K Units) Figure 5. Global NASH Drug Pipeline Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global NASH Drug Pipeline Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Type I Image Figure 10. Type II Image Figure 11. Global NASH Drug Pipeline Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global NASH Drug Pipeline Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global NASH Drug Pipeline Sales Volume Share by Type (2021-2032) Figure 14. Global NASH Drug Pipeline Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global NASH Drug Pipeline Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global NASH Drug Pipeline Sales Value Share by Type (2021-2032) Figure 17. Clinical Image Figure 18. Academic Research Image Figure 19. Global NASH Drug Pipeline Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global NASH Drug Pipeline Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global NASH Drug Pipeline Sales Volume Share by Application (2021-2032) Figure 22. Global NASH Drug Pipeline Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global NASH Drug Pipeline Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global NASH Drug Pipeline Sales Value Share by Application (2021-2032) Figure 25. Global NASH Drug Pipeline Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 26. Global NASH Drug Pipeline Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global NASH Drug Pipeline Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global NASH Drug Pipeline Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America NASH Drug Pipeline Sales Value (2021-2032) & (US$ Million) Figure 30. North America NASH Drug Pipeline Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe NASH Drug Pipeline Sales Value (2021-2032) & (US$ Million) Figure 32. Europe NASH Drug Pipeline Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific NASH Drug Pipeline Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific NASH Drug Pipeline Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America NASH Drug Pipeline Sales Value (2021-2032) & (US$ Million) Figure 36. South America NASH Drug Pipeline Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa NASH Drug Pipeline Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa NASH Drug Pipeline Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA NASH Drug Pipeline Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada NASH Drug Pipeline Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico NASH Drug Pipeline Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany NASH Drug Pipeline Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France NASH Drug Pipeline Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. NASH Drug Pipeline Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy NASH Drug Pipeline Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain NASH Drug Pipeline Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia NASH Drug Pipeline Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands NASH Drug Pipeline Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries NASH Drug Pipeline Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China NASH Drug Pipeline Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan NASH Drug Pipeline Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea NASH Drug Pipeline Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India NASH Drug Pipeline Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia NASH Drug Pipeline Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia NASH Drug Pipeline Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil NASH Drug Pipeline Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina NASH Drug Pipeline Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile NASH Drug Pipeline Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia NASH Drug Pipeline Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru NASH Drug Pipeline Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia NASH Drug Pipeline Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel NASH Drug Pipeline Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE NASH Drug Pipeline Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey NASH Drug Pipeline Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran NASH Drug Pipeline Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt NASH Drug Pipeline Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. NASH Drug Pipeline Value Chain Figure 124. Manufacturing Cost Structure Figure 125. NASH Drug Pipeline Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Applications
  • Clinical
  • Academic Research
Companies covered
  • 89bio Inc
  • ABIONYX Pharma SA
  • Abivax SA
  • Abliva AB
  • Acquist Therapeutics
  • AdAlta Ltd
  • Afimmune Biopharma Ltd
  • Allergan
  • ChemomAb Ltd
  • Dicerna Pharmaceuticals Inc
  • DURECT Corp
  • Eli Lilly and Co
  • Enanta Pharmaceuticals Inc
  • EncuraGen Inc
  • Engitix Ltd
  • Galectin
  • Genfit
  • Gilead
  • Heprotech Inc
  • Hinova Pharmaceuticals Inc
  • HK inno.N Corp
  • HotSpot Therapeutics Inc
  • Immuron
  • Intercept
  • Madrigal
  • Zhejiang Doer Biologics Corp

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global NASH Drug Pipeline Sales Value (2021-2032)
  4. 1.2.2 Global NASH Drug Pipeline Sales Volume (2021-2032)
  5. 1.2.3 Global NASH Drug Pipeline Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 NASH Drug Pipeline Market Dynamics
  1. 2.1 NASH Drug Pipeline Industry Trends
  2. 2.2 NASH Drug Pipeline Industry Drivers
  3. 2.3 NASH Drug Pipeline Industry Opportunities and Challenges
  4. 2.4 NASH Drug Pipeline Industry Restraints
3 NASH Drug Pipeline Market by Company
  1. 3.1 Global NASH Drug Pipeline Company Revenue Ranking in 2025
  2. 3.2 Global NASH Drug Pipeline Revenue by Company (2021-2026)
  3. 3.3 Global NASH Drug Pipeline Sales Volume by Company (2021-2026)
  4. 3.4 Global NASH Drug Pipeline Average Price by Company (2021-2026)
  5. 3.5 Global NASH Drug Pipeline Company Ranking (2024-2026)
  6. 3.6 Global NASH Drug Pipeline Company Manufacturing Base and Headquarters
  7. 3.7 Global NASH Drug Pipeline Company Product Type and Application
  8. 3.8 Global NASH Drug Pipeline Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global NASH Drug Pipeline Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 NASH Drug Pipeline Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 NASH Drug Pipeline Market by Type
  1. 4.1 NASH Drug Pipeline Type Introduction
  2. 4.1.1 By Molecule Types
  3. 4.1.2 By Route of Administration:
  4. 4.1.3 By Mechanism of Action
  5. 4.2 Global NASH Drug Pipeline Sales Volume by Type
  6. 4.2.1 Global NASH Drug Pipeline Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global NASH Drug Pipeline Sales Volume by Type (2021-2032)
  8. 4.2.3 Global NASH Drug Pipeline Sales Volume Share by Type (2021-2032)
  9. 4.3 Global NASH Drug Pipeline Sales Value by Type
  10. 4.3.1 Global NASH Drug Pipeline Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global NASH Drug Pipeline Sales Value by Type (2021-2032)
  12. 4.3.3 Global NASH Drug Pipeline Sales Value Share by Type (2021-2032)
5 NASH Drug Pipeline Market by Application
  1. 5.1 NASH Drug Pipeline Application Introduction
  2. 5.1.1 Clinical
  3. 5.1.2 Academic Research
  4. 5.2 Global NASH Drug Pipeline Sales Volume by Application
  5. 5.2.1 Global NASH Drug Pipeline Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global NASH Drug Pipeline Sales Volume by Application (2021-2032)
  7. 5.2.3 Global NASH Drug Pipeline Sales Volume Share by Application (2021-2032)
  8. 5.3 Global NASH Drug Pipeline Sales Value by Application
  9. 5.3.1 Global NASH Drug Pipeline Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global NASH Drug Pipeline Sales Value by Application (2021-2032)
  11. 5.3.3 Global NASH Drug Pipeline Sales Value Share by Application (2021-2032)
6 NASH Drug Pipeline Regional Sales and Value Analysis
  1. 6.1 Global NASH Drug Pipeline Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global NASH Drug Pipeline Sales by Region (2021-2032)
  3. 6.2.1 Global NASH Drug Pipeline Sales by Region: 2021-2026
  4. 6.2.2 Global NASH Drug Pipeline Sales by Region (2027-2032)
  5. 6.3 Global NASH Drug Pipeline Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global NASH Drug Pipeline Sales Value by Region (2021-2032)
  7. 6.4.1 Global NASH Drug Pipeline Sales Value by Region: 2021-2026
  8. 6.4.2 Global NASH Drug Pipeline Sales Value by Region (2027-2032)
  9. 6.5 Global NASH Drug Pipeline Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America NASH Drug Pipeline Sales Value (2021-2032)
  12. 6.6.2 North America NASH Drug Pipeline Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe NASH Drug Pipeline Sales Value (2021-2032)
  15. 6.7.2 Europe NASH Drug Pipeline Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific NASH Drug Pipeline Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific NASH Drug Pipeline Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America NASH Drug Pipeline Sales Value (2021-2032)
  21. 6.9.2 South America NASH Drug Pipeline Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa NASH Drug Pipeline Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa NASH Drug Pipeline Sales Value Share by Country, 2025 VS 2032
7 NASH Drug Pipeline Country-level Sales and Value Analysis
  1. 7.1 Global NASH Drug Pipeline Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global NASH Drug Pipeline Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global NASH Drug Pipeline Sales by Country (2021-2032)
  4. 7.3.1 Global NASH Drug Pipeline Sales by Country (2021-2026)
  5. 7.3.2 Global NASH Drug Pipeline Sales by Country (2027-2032)
  6. 7.4 Global NASH Drug Pipeline Sales Value by Country (2021-2032)
  7. 7.4.1 Global NASH Drug Pipeline Sales Value by Country (2021-2026)
  8. 7.4.2 Global NASH Drug Pipeline Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA NASH Drug Pipeline Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada NASH Drug Pipeline Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico NASH Drug Pipeline Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany NASH Drug Pipeline Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France NASH Drug Pipeline Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. NASH Drug Pipeline Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy NASH Drug Pipeline Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain NASH Drug Pipeline Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia NASH Drug Pipeline Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands NASH Drug Pipeline Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries NASH Drug Pipeline Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China NASH Drug Pipeline Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan NASH Drug Pipeline Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea NASH Drug Pipeline Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India NASH Drug Pipeline Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia NASH Drug Pipeline Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia NASH Drug Pipeline Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil NASH Drug Pipeline Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina NASH Drug Pipeline Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile NASH Drug Pipeline Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia NASH Drug Pipeline Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru NASH Drug Pipeline Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia NASH Drug Pipeline Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel NASH Drug Pipeline Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE NASH Drug Pipeline Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey NASH Drug Pipeline Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran NASH Drug Pipeline Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt NASH Drug Pipeline Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt NASH Drug Pipeline Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt NASH Drug Pipeline Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 89bio Inc
  2. 8.1.1 89bio Inc Company Information
  3. 8.1.2 89bio Inc Business Overview
  4. 8.1.3 89bio Inc NASH Drug Pipeline Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 89bio Inc NASH Drug Pipeline Product Portfolio
  6. 8.1.5 89bio Inc Recent Developments
  7. 8.2 ABIONYX Pharma SA
  8. 8.2.1 ABIONYX Pharma SA Company Information
  9. 8.2.2 ABIONYX Pharma SA Business Overview
  10. 8.2.3 ABIONYX Pharma SA NASH Drug Pipeline Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 ABIONYX Pharma SA NASH Drug Pipeline Product Portfolio
  12. 8.2.5 ABIONYX Pharma SA Recent Developments
  13. 8.3 Abivax SA
  14. 8.3.1 Abivax SA Company Information
  15. 8.3.2 Abivax SA Business Overview
  16. 8.3.3 Abivax SA NASH Drug Pipeline Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Abivax SA NASH Drug Pipeline Product Portfolio
  18. 8.3.5 Abivax SA Recent Developments
  19. 8.4 Abliva AB
  20. 8.4.1 Abliva AB Company Information
  21. 8.4.2 Abliva AB Business Overview
  22. 8.4.3 Abliva AB NASH Drug Pipeline Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Abliva AB NASH Drug Pipeline Product Portfolio
  24. 8.4.5 Abliva AB Recent Developments
  25. 8.5 Acquist Therapeutics
  26. 8.5.1 Acquist Therapeutics Company Information
  27. 8.5.2 Acquist Therapeutics Business Overview
  28. 8.5.3 Acquist Therapeutics NASH Drug Pipeline Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Acquist Therapeutics NASH Drug Pipeline Product Portfolio
  30. 8.5.5 Acquist Therapeutics Recent Developments
  31. 8.6 AdAlta Ltd
  32. 8.6.1 AdAlta Ltd Company Information
  33. 8.6.2 AdAlta Ltd Business Overview
  34. 8.6.3 AdAlta Ltd NASH Drug Pipeline Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 AdAlta Ltd NASH Drug Pipeline Product Portfolio
  36. 8.6.5 AdAlta Ltd Recent Developments
  37. 8.7 Afimmune Biopharma Ltd
  38. 8.7.1 Afimmune Biopharma Ltd Company Information
  39. 8.7.2 Afimmune Biopharma Ltd Business Overview
  40. 8.7.3 Afimmune Biopharma Ltd NASH Drug Pipeline Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Afimmune Biopharma Ltd NASH Drug Pipeline Product Portfolio
  42. 8.7.5 Afimmune Biopharma Ltd Recent Developments
  43. 8.8 Allergan
  44. 8.8.1 Allergan Company Information
  45. 8.8.2 Allergan Business Overview
  46. 8.8.3 Allergan NASH Drug Pipeline Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Allergan NASH Drug Pipeline Product Portfolio
  48. 8.8.5 Allergan Recent Developments
  49. 8.9 ChemomAb Ltd
  50. 8.9.1 ChemomAb Ltd Company Information
  51. 8.9.2 ChemomAb Ltd Business Overview
  52. 8.9.3 ChemomAb Ltd NASH Drug Pipeline Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 ChemomAb Ltd NASH Drug Pipeline Product Portfolio
  54. 8.9.5 ChemomAb Ltd Recent Developments
  55. 8.10 Dicerna Pharmaceuticals Inc
  56. 8.10.1 Dicerna Pharmaceuticals Inc Company Information
  57. 8.10.2 Dicerna Pharmaceuticals Inc Business Overview
  58. 8.10.3 Dicerna Pharmaceuticals Inc NASH Drug Pipeline Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Dicerna Pharmaceuticals Inc NASH Drug Pipeline Product Portfolio
  60. 8.10.5 Dicerna Pharmaceuticals Inc Recent Developments
  61. 8.11 DURECT Corp
  62. 8.11.1 DURECT Corp Company Information
  63. 8.11.2 DURECT Corp Business Overview
  64. 8.11.3 DURECT Corp NASH Drug Pipeline Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 DURECT Corp NASH Drug Pipeline Product Portfolio
  66. 8.11.5 DURECT Corp Recent Developments
  67. 8.12 Eli Lilly and Co
  68. 8.12.1 Eli Lilly and Co Company Information
  69. 8.12.2 Eli Lilly and Co Business Overview
  70. 8.12.3 Eli Lilly and Co NASH Drug Pipeline Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Eli Lilly and Co NASH Drug Pipeline Product Portfolio
  72. 8.12.5 Eli Lilly and Co Recent Developments
  73. 8.13 Enanta Pharmaceuticals Inc
  74. 8.13.1 Enanta Pharmaceuticals Inc Company Information
  75. 8.13.2 Enanta Pharmaceuticals Inc Business Overview
  76. 8.13.3 Enanta Pharmaceuticals Inc NASH Drug Pipeline Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Enanta Pharmaceuticals Inc NASH Drug Pipeline Product Portfolio
  78. 8.13.5 Enanta Pharmaceuticals Inc Recent Developments
  79. 8.14 EncuraGen Inc
  80. 8.14.1 EncuraGen Inc Company Information
  81. 8.14.2 EncuraGen Inc Business Overview
  82. 8.14.3 EncuraGen Inc NASH Drug Pipeline Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 EncuraGen Inc NASH Drug Pipeline Product Portfolio
  84. 8.14.5 EncuraGen Inc Recent Developments
  85. 8.15 Engitix Ltd
  86. 8.15.1 Engitix Ltd Company Information
  87. 8.15.2 Engitix Ltd Business Overview
  88. 8.15.3 Engitix Ltd NASH Drug Pipeline Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Engitix Ltd NASH Drug Pipeline Product Portfolio
  90. 8.15.5 Engitix Ltd Recent Developments
  91. 8.16 Galectin
  92. 8.16.1 Galectin Company Information
  93. 8.16.2 Galectin Business Overview
  94. 8.16.3 Galectin NASH Drug Pipeline Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Galectin NASH Drug Pipeline Product Portfolio
  96. 8.16.5 Galectin Recent Developments
  97. 8.17 Genfit
  98. 8.17.1 Genfit Company Information
  99. 8.17.2 Genfit Business Overview
  100. 8.17.3 Genfit NASH Drug Pipeline Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Genfit NASH Drug Pipeline Product Portfolio
  102. 8.17.5 Genfit Recent Developments
  103. 8.18 Gilead
  104. 8.18.1 Gilead Company Information
  105. 8.18.2 Gilead Business Overview
  106. 8.18.3 Gilead NASH Drug Pipeline Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Gilead NASH Drug Pipeline Product Portfolio
  108. 8.18.5 Gilead Recent Developments
  109. 8.19 Heprotech Inc
  110. 8.19.1 Heprotech Inc Company Information
  111. 8.19.2 Heprotech Inc Business Overview
  112. 8.19.3 Heprotech Inc NASH Drug Pipeline Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Heprotech Inc NASH Drug Pipeline Product Portfolio
  114. 8.19.5 Heprotech Inc Recent Developments
  115. 8.20 Hinova Pharmaceuticals Inc
  116. 8.20.1 Hinova Pharmaceuticals Inc Company Information
  117. 8.20.2 Hinova Pharmaceuticals Inc Business Overview
  118. 8.20.3 Hinova Pharmaceuticals Inc NASH Drug Pipeline Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Hinova Pharmaceuticals Inc NASH Drug Pipeline Product Portfolio
  120. 8.20.5 Hinova Pharmaceuticals Inc Recent Developments
  121. 8.21 HK inno.N Corp
  122. 8.21.1 HK inno.N Corp Company Information
  123. 8.21.2 HK inno.N Corp Business Overview
  124. 8.21.3 HK inno.N Corp NASH Drug Pipeline Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 HK inno.N Corp NASH Drug Pipeline Product Portfolio
  126. 8.21.5 HK inno.N Corp Recent Developments
  127. 8.22 HotSpot Therapeutics Inc
  128. 8.22.1 HotSpot Therapeutics Inc Company Information
  129. 8.22.2 HotSpot Therapeutics Inc Business Overview
  130. 8.22.3 HotSpot Therapeutics Inc NASH Drug Pipeline Sales, Value and Gross Margin (2021-2026)
  131. 8.22.4 HotSpot Therapeutics Inc NASH Drug Pipeline Product Portfolio
  132. 8.22.5 HotSpot Therapeutics Inc Recent Developments
  133. 8.23 Immuron
  134. 8.23.1 Immuron Company Information
  135. 8.23.2 Immuron Business Overview
  136. 8.23.3 Immuron NASH Drug Pipeline Sales, Value and Gross Margin (2021-2026)
  137. 8.23.4 Immuron NASH Drug Pipeline Product Portfolio
  138. 8.23.5 Immuron Recent Developments
  139. 8.24 Intercept
  140. 8.24.1 Intercept Company Information
  141. 8.24.2 Intercept Business Overview
  142. 8.24.3 Intercept NASH Drug Pipeline Sales, Value and Gross Margin (2021-2026)
  143. 8.24.4 Intercept NASH Drug Pipeline Product Portfolio
  144. 8.24.5 Intercept Recent Developments
  145. 8.25 Madrigal
  146. 8.25.1 Madrigal Company Information
  147. 8.25.2 Madrigal Business Overview
  148. 8.25.3 Madrigal NASH Drug Pipeline Sales, Value and Gross Margin (2021-2026)
  149. 8.25.4 Madrigal NASH Drug Pipeline Product Portfolio
  150. 8.25.5 Madrigal Recent Developments
  151. 8.26 Zhejiang Doer Biologics Corp
  152. 8.26.1 Zhejiang Doer Biologics Corp Company Information
  153. 8.26.2 Zhejiang Doer Biologics Corp Business Overview
  154. 8.26.3 Zhejiang Doer Biologics Corp NASH Drug Pipeline Sales, Value and Gross Margin (2021-2026)
  155. 8.26.4 Zhejiang Doer Biologics Corp NASH Drug Pipeline Product Portfolio
  156. 8.26.5 Zhejiang Doer Biologics Corp Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 NASH Drug Pipeline Value Chain Analysis
  2. 9.1.1 NASH Drug Pipeline Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 NASH Drug Pipeline Sales Mode & Process
  6. 9.2 NASH Drug Pipeline Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 NASH Drug Pipeline Distributors
  9. 9.2.3 NASH Drug Pipeline Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst